CA
NZ
UK
AU
IND
US
…
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Citius Oncology, Inc. (NASDAQ: CTOR) is limited. The company appears to be a clinical-stage biotechnology firm focused on developing oncology therapeutics and delivery technologies, and its long-term growth drivers may include progress in clinical trials, regulatory approvals, and partnerships or licensing that could support commercialization and may attract investors seeking exposure to novel cancer therapies.
Material risks include high dependency on successful clinical and regulatory outcomes, limited or no commercial revenue, and likely need for external financing that could dilute shareholders or constrain development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -23.70M | -20.57M | -12.12M | -9.71M | -0.01M |
| Net income | -24.76M | -21.15M | -12.70M | -10.87M | -0.01M |
| Selling general administrative | 17.10M | 15.65M | 7.88M | 2.86M | - |
| Ebit | - | -20.57M | -12.12M | -4.86M | - |
| Ebitda | -23.49M | -20.57M | -12.12M | -4.86M | -0.01M |
| Depreciation and amortization | - | - | - | 9.71M | - |
| Operating income | -23.52M | -20.57M | -12.12M | -9.71M | - |
| Other operating expenses | 23.52M | 20.57M | 12.12M | 9.71M | - |
| Interest expense | 0.22M | 0.00M | - | - | - |
| Tax provision | 1.06M | 0.58M | 0.58M | 0.58M | - |
| Interest income | 0.04M | 0.00M | - | - | - |
| Net interest income | -0.18M | 0.00M | - | - | - |
| Income tax expense | 1.06M | 0.58M | 0.58M | 1.15M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 23.52M | 20.57M | 12.12M | 9.71M | - |
| Total other income expense net | -0.18M | - | - | - | -0.01M |
| Net income from continuing ops | -24.76M | -21.15M | -12.70M | -5.43M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 100.94M | 84.37M | 47.73M | 42.69M | - |
| Intangible assets | 73.40M | 73.40M | 40.00M | 40.00M | - |
| Other current assets | 1.33M | 2.70M | 7.73M | 2.69M | - |
| Total liab | 56.08M | 38.23M | 22.20M | 6.42M | - |
| Total stockholder equity | 44.87M | 46.14M | 25.54M | 36.27M | - |
| Other current liab | 36.26M | 28.99M | 19.76M | 5.75M | - |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | - |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | - |
| Retained earnings | -64.04M | -39.28M | -18.13M | -5.43M | - |
| Cash | 3.92M | 0.00M | 0.03M | 0.29M | - |
| Total current liabilities | 49.49M | 32.70M | 21.05M | 5.85M | - |
| Net debt | -0.12M | 3.80M | -0.03M | -0.29M | - |
| Short long term debt total | 3.80M | 3.80M | - | - | - |
| Other stockholder equity | 108.90M | 85.41M | 43.66M | 41.69M | - |
| Total current assets | 27.54M | 10.97M | 7.73M | 2.69M | - |
| Long term debt | 3.80M | 3.80M | - | - | - |
| Inventory | 22.29M | 8.27M | 0.00M | - | - |
| Accounts payable | 13.23M | 3.71M | 1.29M | 0.09M | - |
| Non currrent assets other | 73.40M | 73.40M | 40.00M | 40.00M | - |
| Non current assets total | 73.40M | 73.40M | 40.00M | 40.00M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
| Investments | - | -5.00M | 0.00M | - |
| Total cashflows from investing activities | -5.75M | -5.00M | -1.32M | -67.32M |
| Net borrowings | 0.00M | 3.80M | 0.00M | - |
| Total cash from financing activities | 15.17M | 4.87M | 1.66M | 67.66M |
| Net income | -24.76M | -21.15M | 2.42M | 0.38M |
| Change in cash | 3.92M | -0.03M | -0.26M | 0.29M |
| Begin period cash flow | 0.00M | 0.03M | 0.29M | 0.00M |
| End period cash flow | 3.92M | 0.00M | 0.03M | 0.29M |
| Total cash from operating activities | -5.49M | 0.13M | -0.60M | -0.05M |
| Issuance of capital stock | 15.17M | 0.00M | - | - |
| Other cashflows from investing activities | -5.75M | -5.00M | - | - |
| Change to inventory | -12.65M | -2.13M | 0.00M | - |
| Change to account receivables | - | - | 0.35M | 0.03M |
| Other cashflows from financing activities | - | 1.07M | 1.66M | -0.38M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 9.89M | 13.20M | 0.41M | 0.06M |
| Stock based compensation | 8.32M | 7.50M | 1.97M | 0.00M |
| Other non cash items | 8.32M | 7.50M | -3.43M | -0.49M |
| Free cash flow | -5.49M | 0.13M | -0.60M | -0.05M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| CTOR Citius Oncology, Inc. |
0.00 0.41% |
0.61 | - | 35.59 | 20.14 | 1.36 | 19.25 |
| MKKGY Merck KGaA ADR |
0.32 0.99% |
32.57 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
158.72 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.18 0.91% |
20.09 | - | 10.96 | 0.01 | 1.20 | 2.94 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
-3.18 7.73% |
37.97 | - | 10.66 | 0.01 | 1.16 | 2.94 |
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
11 Commerce Drive, Cranford, NJ, United States, 07016
908 967 6677
| Name | Title | Year Born |
|---|---|---|
| Mr. Leonard L. Mazur | CEO, President & Executive Chairman | 1945 |
| Mr. Myron Z. Holubiak | Secretary & Executive Vice Chairman | 1947 |
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer | 1960 |
| Mr. Jaime Bartushak | Chief Financial Officer & Treasurer | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.80%
Consumer Cyclical
-0.28%
Consumer Defensive
-0.47%
Energy
+0.39%
Financial Services
-0.37%
Financials
-0.92%
Healthcare
+0.69%
Industrials
+0.14%
Real Estate
-0.41%
Technology
+0.14%
Utilities
-0.27%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...